Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs PRCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: UFPT 5 – 1 PRCT Matrix Metrics: UFPT 8 – 2 PRCT

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over PROCEPT BioRobotics Corporation (PRCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas PRCT carries 33.6/100 (SELL) at $23.54 (N/M Forward P/E, -34.5% operating margin).

  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile PRCT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs PRCT
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
PRCT NASDAQ
PROCEPT BioRobotics Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$23.54
-1.09% 1D
Market Cap $1.4B
TTM Revenue $352M
Forward P/E N/M
Beta / 30D Vol 0.69β · 62% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 50.0 Fund 33.0 Flow 58.0 Mom 31.8
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.2 · SMA20: $20.90 · SMA50: $19.53

6-Pillar Scorecard Institutional Category Breakdown (UFPT 5 – 1 PRCT)

Columns: Metric · UFPT · PRCT
1. Valuation Multiples UFPT
Forward P/E 24.7x N/M
Trailing P/E 31.2x N/M
PEG Ratio 3.80x N/M
EV / Revenue 3.6x 3.5x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% +18.0%
Earnings Growth (YoY) +25.1% +0.0%
TTM Revenue (USD) $650M $352M
Market Cap $2.4B $1.4B
3. Profitability & Quality UFPT
Gross Margin 28.9% 63.7%
Operating Margin 15.4% -34.5%
Net Profit Margin 11.8% -32.6%
Return on Equity (ROE) 17.2% -32.4%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) $120M EBITDA -$85M
Cash Flow Margin 18.5% EBITDA Mgn -24.1%
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $141M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRCT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 42.3% (3rd %ile) 76.8% (23rd %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat UFPT
OpEx & R&D Intensity 13.5% of Rev ($88M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (8) vs PRCT (2)
Institutional Metric UFPT PRCT Criterion Row Edge
Market Capitalization
Scale
$2.4B $1.4B Larger Scale UFPT
Trailing P/E Ratio
Valuation
31.2x N/M Lower Multiple UFPT
Forward P/E Ratio
Valuation
24.7x N/M Lower Multiple UFPT
Revenue Growth (YoY)
Growth
+11.6% +18.0% Higher Growth PRCT
Operating Margin (TTM)
Profitability
15.4% -34.5% Higher Margin UFPT
Net Profit Margin
Profitability
11.8% -32.6% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
17.2% -32.4% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 33% ($17–$37) Stronger Trend UFPT
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 0.69β · 62% Vol Lower Realized Risk PRCT
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 33.6 / 100 (SELL) Higher Composite UFPT
Trailing 12M Revenue (USD)
Operating Scale
$650M $352M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 63.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev N/M PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) -$85M ($141M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRCT +31.62 pp
UFPT: +2.36% · PRCT: +33.98%
3M Horizon PRCT +15.33 pp
UFPT: -4.92% · PRCT: +10.41%
6M Horizon UFPT +46.94 pp
UFPT: +37.44% · PRCT: -9.5%
1Y Horizon UFPT +50.04 pp
UFPT: +27.42% · PRCT: -22.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs PRCT. Trailing 12-month operating profitability (UFPT 15.4% vs PRCT -34.5%) and valuation multiples (UFPT 24.7x vs PRCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
PRCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$352M
Gross Margin63.7%
Op. Margin-34.5%
ROE / Fwd P/E-32.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRCT CONSOLIDATION
68d in phase · OBV ACCUMULATION
Current IV 76.8%
IV Percentile 23rd %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
PRCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.4B market capitalization and -34.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs PRCT Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over PROCEPT BioRobotics Corporation (PRCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas PRCT carries 33.6/100 (SELL) at $23.54 (N/M Forward P/E, -34.5% operating margin). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile PRCT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with PRCT at +18.0% YoY revenue growth and +0.0% YoY earnings growth on $352M TTM revenue (63.7% gross margin, -34.5% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $352M for PRCT. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRCT.

UFPT screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas PRCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.5x EV/Revenue (-24.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus PRCT (-32.4% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, PRCT carries 76.8% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.69β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.